Table 2.
Clinical features of stroke patients taking direct oral anticoagulants who underwent acute reperfusion therapy: the NCVC Stroke Registry
| Intravenous alteplase (n=8) | Endovascular therapy alone (n=9) | Intravenous alteplase and endovascular therapy combined (n=5) | |
|---|---|---|---|
| Women | 0 (0) | 2 (22) | 1 (20) |
| Age (yr) | 73 (56–89) | 76 (48–90) | 75 (65–91) |
| DOACs | Dabigatran in 3, apixaban in 2, edoxaban in 3 | Dabigatran in 4, rivaroxaban in 4, edoxaban in 2 | Dabigatran in 1, apixaban in 4 |
| Indication for DOAC medication | Identified NVAF: 8 | Identified NVAF: 7 | Identified NVAF: 4 |
| Suspicion of NVAF: 1, DVT: 1 | Suspicion of NVAF: 1 | ||
| Combined use of antiplatelets | 0 (0) | 0 (0) | 1 (20) |
| Initial aPTT for dabigatran users (sec) | 31 (29–31) | 34.5 (30–44) | 33 ( |
| Initial INR for Xa inhibitor users | 1.12 (1.02–1.43) | 1.19 (0.94–2.91) | 1.23 (1.16–1.36) |
| Anterior territory stroke | 7 (88) | 7 (78) | 5 (100) |
| DWI-ASPECTS* | 8 (5–10) | 7 (4–10) | 7.5 (7–10) |
| Dosing-to-treatment time (hr) | 15.8 (5.6–83.3) | 4.5 (2.4–26.8) | 6.5 (3.3–22.9) |
| Onset-to-treatment time (hr) | 1.7 (1.0–3.6) | 2.4 (1.5–4.1) | 2.1 (1.1–3.5) |
| TICI (0/1/2a/2b/3) | - | 1/1/1/2/4 | 2/0/0/3/0 |
| National Institutes of Health Stroke Scale score | |||
| At baseline | 15.5 (1–20) | 21 (5–31) | 16 (13–33) |
| At 24 hr | 4 (0–20) | 4 (3–22) | 15 (9–30) |
| At 7 day | 2 (0–20) | 4 (0–17) | 16 (5–31) |
| Any ICH <36 hr | 0 (0) | 1 (11) | 3 (60) |
| Symptomatic ICH <36 hr† | 0 (0) | 0 (0) | 1 (20)‡ |
| Modified Rankin Scale score at 3 months (0-1/2/3/4/5/6) | 3/2/1/1/1/0 | 3/0/1/5/0/0 | 0/1/1/0/1/2§ |
Values are presented as number (%) or median (range).
NCVC, National Cerebral and Cardiovascular Center; DOAC, direct oral anticoagulant; NVAF, non-valvular atrial fibrillation; DVT, deep vein thrombosis; aPTT, activated partial thromboplastin time; INR, international normalized ratio; DWI-ASPECTS, diffusion-weighted image Alberta Stroke Program Early CT Score; TICI, thrombolysis in cerebral infarction; ICH, intracranial hemorrhage.
Only for patients with anterior territory stroke;
ICH with any neurological deterioration;
Developing subarachnoid hemorrhage;
One patient died of acute heart failure on day 88 and another of bile duct cancer on day 23.